Twist Bioscience (NASDAQ:TWST) Stock Price Up 5.8% – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST) shares rose 5.8% during trading on Wednesday . The stock traded as high as $147.98 and last traded at $146.0890. 220,798 shares changed hands during trading, a decline of 85% from the average daily volume of 1,520,436 shares. The stock had previously closed at $138.10.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Barclays boosted their price target on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Piper Sandler upped their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Leerink Partners upped their target price on Twist Bioscience from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, UBS Group initiated coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $103.00.

Twist Bioscience Stock Up 8.7%

The firm’s fifty day moving average price is $117.46 and its two-hundred day moving average price is $82.21. The stock has a market cap of $9.75 billion, a price-to-earnings ratio of -70.07 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the prior year, the business earned $0.33 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 193,109 shares of company stock valued at $24,049,024 in the last quarter. Corporate insiders own 3.08% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. William Blair Investment Management LLC raised its holdings in Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after buying an additional 1,812,146 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at $600,191,000. Bank of America Corp DE bought a new stake in Twist Bioscience during the second quarter worth about $94,922,000. Allspring Global Investments Holdings LLC bought a new position in Twist Bioscience in the 1st quarter worth about $22,563,000. Finally, BNP Paribas Financial Markets lifted its position in Twist Bioscience by 242.2% in the 4th quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock valued at $13,183,000 after acquiring an additional 294,144 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.